Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Operating Expenses: 2023-2024

Historic Operating Expenses for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $331.6 million.

  • Inhibrx Biosciences' Operating Expenses fell 27.75% to $33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.4 million, marking a year-over-year decrease of 58.17%. This contributed to the annual value of $331.6 million for FY2024, which is 50.05% up from last year.
  • According to the latest figures from FY2024, Inhibrx Biosciences' Operating Expenses is $331.6 million, which was up 50.05% from $221.0 million recorded in FY2023.
  • Inhibrx Biosciences' 5-year Operating Expenses high stood at $331.6 million for FY2024, and its period low was $221.0 million during FY2023.
  • Over the past 2 years, Inhibrx Biosciences' median Operating Expenses value was $276.3 million (recorded in 2023), while the average stood at $276.3 million.
  • Data for Inhibrx Biosciences' Operating Expenses shows a peak YoY surged of 50.05% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Operating Expenses (Yearly) stood at $221.0 million in 2023, then spiked by 50.05% to $331.6 million in 2024.